GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Ltd (OTCPK:AMEUF) » Definitions » EV-to-EBIT

Anteris Technologies (Anteris Technologies) EV-to-EBIT : -5.04 (As of May. 21, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Anteris Technologies EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Anteris Technologies's Enterprise Value is $232.77 Mil. Anteris Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-46.18 Mil. Therefore, Anteris Technologies's EV-to-EBIT for today is -5.04.

The historical rank and industry rank for Anteris Technologies's EV-to-EBIT or its related term are showing as below:

AMEUF' s EV-to-EBIT Range Over the Past 10 Years
Min: -36.35   Med: -4.27   Max: 0.06
Current: -5.04

During the past 13 years, the highest EV-to-EBIT of Anteris Technologies was 0.06. The lowest was -36.35. And the median was -4.27.

AMEUF's EV-to-EBIT is ranked worse than
100% of 457 companies
in the Medical Devices & Instruments industry
Industry Median: 20.17 vs AMEUF: -5.04

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Anteris Technologies's Enterprise Value for the quarter that ended in Dec. 2023 was $216.31 Mil. Anteris Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-46.18 Mil. Anteris Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -21.35%.


Anteris Technologies EV-to-EBIT Historical Data

The historical data trend for Anteris Technologies's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anteris Technologies EV-to-EBIT Chart

Anteris Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.95 -1.53 -5.94 -6.82 -4.54

Anteris Technologies Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.94 - -6.82 - -4.54

Competitive Comparison of Anteris Technologies's EV-to-EBIT

For the Medical Devices subindustry, Anteris Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anteris Technologies's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Anteris Technologies's EV-to-EBIT falls into.



Anteris Technologies EV-to-EBIT Calculation

Anteris Technologies's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=232.771/-46.184
=-5.04

Anteris Technologies's current Enterprise Value is $232.77 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anteris Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-46.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anteris Technologies  (OTCPK:AMEUF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Anteris Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-46.184/216.30764
=-21.35 %

Anteris Technologies's Enterprise Value for the quarter that ended in Dec. 2023 was $216.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anteris Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-46.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anteris Technologies EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Anteris Technologies's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Anteris Technologies (Anteris Technologies) Business Description

Traded in Other Exchanges
Address
Level 3, 9 Sherwood Road, Suite 302, Toowong Tower, Toowong, QLD, AUS, 4066
Anteris Technologies Ltd is a structural heart company engaged in delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. The group's solutions include Anteris' DurAVR transcatheter heart valve for younger patients who need a heart valve that will last their lifetime, as well as DurAVR with its biomimetic design that replicates the normal blood flow of a healthy human aortic valve. The company derives key revenue from Australia and the U.S.